Inpharma 1629 - 15 Mar 2008

■ Olmesartan medoxomil enhances nocturnal BPreduction, possibly through increased daytimenatriuresis. Researchers from Japan evaluated datafrom 20 patients with chronic kidney disease (ten withhypertension) who received olmesartan for 8 weeks;doses were titrated, as tolerated, up to 10–40 mg/day .Compared with baseline, olmesartan treatment wasassociated with a reduction in nocturnal BP of17/10mm Hg and daytime BP of 10/5mm Hg. Meanarterial pressure (MAP) fell by 12mm Hg at night butonly 7mm Hg in the day (p = 0.03). The night-timeurinary sodium excretion rate tended to fall, whereasthe day-time excretion increased significantly.Fukuda M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restoresnocturnal blood pressure decline by enhancing daytime natriuresis. Journal ofHypertension 26: 583-588, No. 3, Mar 2008 801104765

1

Inpharma 15 Mar 2008 No. 16291173-8324/10/1629-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved